Cost-utility analysis of the newly recommended adjuvant chemotherapy for resectable gastric cancer patients in the 2011 Chinese National Comprehensive Cancer Network (NCCN) clinical practice guidelines in oncology: Gastric cancer

PharmacoEconomics

Volumn 32, Issue 3, 2014, Pages 235-243

  Chongqing, Tan ^a,b   Liubao, Peng ^a,b   Xiaohui, Zeng ^b   Jianhe, Li ^a   Xiaomin, Wan ^a   Gannong, Chen ^a   Siying, Wang ^b   Lihui, Ouyang ^b   Ziying, Zhao ^b  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; OXALIPLATIN; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; FLUOROURACIL; PLATINUM COMPLEX;

ABDOMINAL PAIN; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURGERY; CHINESE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DIARRHEA; DISEASE FREE SURVIVAL; FOLLOW UP; GASTRECTOMY; GROSS NATIONAL PRODUCT; HEALTH CARE SYSTEM; HUMAN; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MIDDLE AGED; MONTE CARLO METHOD; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; ONCOLOGY; PHASE 3 CLINICAL TRIAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; SOUTH KOREA; STOMACH CANCER; ANALOGS AND DERIVATIVES; CHEMICAL STRUCTURE; COST BENEFIT ANALYSIS; ECONOMICS; MULTICENTER STUDY (TOPIC); PROBABILITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); STOMACH NEOPLASMS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COST-BENEFIT ANALYSIS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FLUOROURACIL; GASTRECTOMY; HUMANS; MARKOV CHAINS; MODELS, MOLECULAR; MULTICENTER STUDIES AS TOPIC; ORGANOPLATINUM COMPOUNDS; PRACTICE GUIDELINES AS TOPIC; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STOMACH NEOPLASMS;

EID: 84896259898     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.1007/s40273-013-0065-2     Document Type: Article

References (28)

1. International Agency for Research on Cancer. Stomach cancer incidence, mortality and prevalence worldwide in 2008 summary. http://globacan.iarc.fr. Accessed 10 July 2012.
2. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: gastric cancer guideline 2011 (Chinese). http://www.nccnchina.org. cn/nccn-guidelines-china.aspx. Accessed 10 July 2012.
3. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: gastric cancer guideline 2010 (Chinese). http://wenku.baidu.com/ view/119d92e819e8b8f67c1cb91b.html. Accessed 10 July 2012.
4. Bang Y-J, Kim Y-W, Yang H-K, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012;379:315-21.
5. National Bureau of Statistics of the People's Republic of China. Gross domestic product. http://www.stats.gov.cn/tjsj/ndsj/2011/html/C0201e.htm. Accessed 6 July 2012.
6. Hunan Pharmaceutical. Medicine prices. http://www.hnyyjg.com/ priceMedicine. Accessed 18 July 2012.
7. WHO. Life table. http://www.who.int. Accessed 14 July 2012.
8. Briggs A, Claxton K, Sculpher M. Decision modeling for health economic evaluation. New York: Oxford University Press; 2006.
9. Wu B, Ye M, Chen H, et al. Costs of trastuzumab in combination with chemotherapy for HER2-positive advanced gastric or gastroesophageal junction cancer: an economic evaluation in the Chinese context. Clin Ther. 2012;34(2):468-79.
10. Liubao P, Xiaomin W, Chongqing T, et al. Cost-effectiveness analysis of adjuvant therapy for operable breast cancer from a Chinese perspective: doxorubicin plus cyclophosphamide versus docetaxel plus cyclophosphamide. Pharmacoeconomics. 2009;27(10):873-86.
11. Wu B, Dong B, Xu Y, et al. Economic evaluation of first-line treatments for metastatic renal cell carcinoma: a cost-effectiveness analysis in a health resource-limited setting. PLoS One. 2012;7(3):e32530.
12. Guangzhou Biaodian Medical Information. Report on antitumor (anticancer) drug market in 2010. http://wenku.baidu.com/view/370ed272f242336c1eb95e22.html. Accessed 2 July 2012.
13. The People's Bank of China. Exchange rate. http://www.pbc.gov.cn. Accessed 17 July 2012.
14. Wilson D, Hiller L, Geh JI. Review of second-line chemotherapy for advanced gastric adenocarcinoma. Clin Oncol (R Coll Radiol). 2005;17:81-9.
15. Munene G, Francis W, Garland SN, et al. The quality of life trajectory of resected gastric cancer. J Surg Oncol. 2012;105:337-41.
16. Sakamaki H, Ikeda S, Yajima S, et al. Cost-utility analysis of the oral fluoropyrimidine S-1 versus conventional intravenous chemotherapy in advanced or recurrent gastric cancer. Open Health Serv Policy J. 2009;2:26-33.
17. International Society for Pharmacoeconomics and Outcomes Research. Chinese guidelines for pharmacoeconomic evaluations (2011). http://www.ispor. org. Accessed 5 July 2012.
18. Yang T, Shen X, Tang X, et al. Phase II trial of oxaliplatin plus oral capecitabine as first-line chemotherapy for patients with advanced gastric cancer. Tumori. 2011;97(4):466-72.
19. Liu C, Sun Q, Hang X, et al. Multicenter phase II study of capecitabine plus oxaliplatin as a first-line therapy in Chinese patients with advanced gastric cancer. Anticancer Drugs. 2008;19(8):825-31.
20. Park YH, Lee JL, Ryoo BY, et al. Capecitabine in combination with oxaliplatin (XELOX) as a first-line therapy for advanced gastric cancer. Cancer Chemother Pharmacol. 2008;61(4):623-9.
21. Jatoi A, Murphy BR, Foster NR, the North Central Cancer Treatment Group, et al. Oxaliplatin and capecitabine in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction and gastric cardia: a phase II study from the North Central Cancer Treatment Group. Ann Oncol. 2006;17:29-34. (Pubitemid 43033836)
22. National Comprehensive Cancer Network. NCCN guidelines: gastric cancer. http://www.nccn.org/professionals/physician-gls/pdf/gastric.pdf. Accessed 5 July 2012.
23. Chen XZ, Jiang K, Hu JK, et al. Cost-effectiveness analysis of chemotherapy for advanced gastric cancer in China. World J Gastroenterol. 2008;14(17):2715-22.
24. Yeh JM, Kuntz KM, Ezzati M, et al. Exploring the cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer in China in anticipation of clinical trial results. Int J Cancer. 2009;124(1):157-66.
25. Yip WCM, Hsiao WC, Chen W, et al. Early appraisal of China's huge and complex health-care reforms. Lancet. 2012;379:833-42.
26. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687-97.
27. Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357:1810-20. (Pubitemid 350044801)
28. Sasako Mitsuru, Sakuramoto Shinichi, Katai Hitoshi, et al. Fiveyear outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011;29(33):4387-93.